RENEWED APPROACH TO THE TREATMENT OF THE GOUT IN FEMALE
Keywords:
gout, women, hyperuricemiaAbstract
Given the central role of hyperuricemia in the pathophysiology of gout, urate lowering therapies, including xanthine oxidase inhibitors, uricosuric agents, and uricases, are employed with the goal of preventing flares, which in turn are most commonly managed with nonsteroidal anti-inflammatory drugs (NSAIDs), colchicine, glucocorticoids, or anti-IL-1β agents. Despite the availability of effective urate-lowering drugs, treatment of gout is often one of the most difficult problems to solve. Aim of the study. To conduct a comparative analysis of hypouricemic drugs in patients with gout. Materials and methods. The study included 55 female patients with a definite diagnosis of gout who applied to the arthrological department on the basis of the multidisciplinary clinic of the Tashkent Medical Academy for the purpose of therapy correction. Allopurinol was used as urate-lowering therapy at a starting dose of 100 mg/day, followed by an increase by 100 mg/day every 2–3 weeks until the target UA level was achieved. In cases of ineffectiveness of the maximum possible doses of allopurinol and/or the presence of adverse reactions associated with this drug, febuxostat was prescribed at an initial dose of 80 mg/day, which, if necessary, was increased to 120 mg/day. Results and discussion. Adherence to regular drug therapy among patients with gout receiving allopurinol was 25% at a high level, 40% at an average level, and 35% at a low level. When using febuxostat, high adherence to therapy was detected in more than 50% of cases. Adherence to high-level lifestyle changes was 30%, medium 40%, low - 30%, and readiness to correct hypouricemic therapy was 38%, 45% and 17%, respectively, by level. Conclusion. Thus, compliance with recommendations for the management of patients with gout allows for high patient adherence to both drug treatment and lifestyle changes.
References
1. Association of Rheumatologists of Russia. Gout. Clinical recommendations. 2018 (Electronic resource.) URL: http://cr.rosminzdrav.ru/#!/recomend/174.
2. Galushko E.A., Nasonov E.L. Prevalence of rheumatic diseases in Russia. Almanac of Clinical Medicine. 2018;46(1):32–39. [Galushko E.A., Nasonov E.L. Prevalence of rheumatic diseases in Russia. Al'manakh klinicheskoi meditsiny. 2018;46(1):32–39 (in Russ.)]. DOI: 10.18786/2072-0505-2018-46-1-32-39.
3. Eliseev M.S. Treatment of gout: problems, paradoxes, prospects. Medical advice. 2020;(2):104–108. DOI: 10.21518/2079-701X-2020-2-104-108
4. Eliseev M.S. Urate-lowering therapy for gout: basic principles and real possibilities. Medical advice. 2017;20:144-150. [Yeliseev M.S. Urate-lowering therapy: basic principles and real opportunities. Meditsinsky Council. 2017;20:144-150.] (In Russ)
5. Lebedev P.A., Garanin A.A., Novichkova N.L. Pharmacotherapy of gout - modern approaches and prospects. Modern rheumatology. 2021;15(4):107–112.
6. Chikina MN, Ilinykh EV, Eliseev MS. Adherence to urate-lowering therapy in compliance with national recommendations for the management of patients with gout (preliminary data). Modern rheumatology. 2020;14(4):70–75. DOI: 10.14412/1996-7012-2020-4-70-75.
7. Tsurko V.V., Gromova M.A. Optimal urate-lowering therapy in patients with gout - a modern interpretation of the problem. RMJ. 2021;7:50-54.
8. itzGerald J.D., Dalbeth N., Mikuls T. et al. 2020 American College of Rheumatology Guideline for the Management of Gout. Arthritis Care Res (Hoboken). 2020;72(6):744–760. DOI: 10.1002/acr.24180.
9. Ganiyeva N.A., Djurayeva E.R., Abduazizova N.X., Aripova N.A., Kasimova M.B., Axmedova N.A., Bekenova G.T. Assessment of clinical and diagnostic aspects of atherosclerosis in patients with systemic scleroderma // Journal of Hunan University Natural Science. – 2023. – Vol. 50. – №7. – Р. 37-47.
10. Juraschek SP, Kovell LC, Miller ER, et al. Gout, urate-lowering therapy, and uric acid levels among adults in the United States. Arthritis Care Res (Hoboken). 2015 Apr;67(4): 588-92. doi: 10.1002/acr.22469.
11. Kuo CF, Grainge MJ, Mallen C, et al. Eligibility for and prescription of urate-lowering treatment in patients with incident gout in England. JAMA. 2014 Dec 24-31;312(24): 2684-6. doi: 10.1001/jama.2014.14484.
12. Tsurko V.V., Morozova T.E., Gromova M.A., Krykhivskaya K.M. Gout: purpose, indications and adherence to urate-lowering therapy. Medical advice. 2019; 1: 72-75. DOI: https://doi.org/10.21518/2079-701X-2019-1-72-75.
